Options Trading Strategies Around FDA Approval Decisions: A Comprehensive Analysis

TL;DR: The U.S. Food and Drug Administration’s (FDA) drug approval decision is one of the most closely watched binary events in biotech options trading. Ahead of the decision date, options’ implied volatility (IV) often rises sharply; once the outcome is announced, IV typically drops rapidly—so-called “volatility crush” (IV Crush). Understanding this mechanism, as well as the options strategies commonly used before and after the decision, can help investors assess potential risks and returns more clearly when participating in these high-volatility events.

In the world of biotech investing, the moment the FDA announces a drug approval outcome is often a period of intense market focus. A single approval can send a stock sharply higher in a short time; a rejection letter can erase years of effort and drive the stock down dramatically. For investors using options to participate in such options events, understanding how the FDA review process works—and the market dynamics before and after the decision—is the first step in doing proper homework.

Starting from the basic concepts of FDA drug approvals, this article examines how implied volatility changes around the decision, introduces the features of common options strategies one by one, and explains the key risks to watch when trading these binary events. Whether you are new to biotech options or looking to deepen your understanding of event-driven trading, this content is presented for objective educational purposes only and does not constitute any investment advice.

What Is an FDA Drug Approval Event?

The U.S. Food and Drug Administration (Food and Drug Administration, FDA) is the federal agency responsible for regulating the marketing of drugs in the United States. When a pharmaceutical or biotech company completes clinical trials and seeks to bring a new drug to market, it must submit a New Drug Application (New Drug Application, NDA) or a Biologics License Application (Biologics License Application, BLA) to the FDA.

The PDUFA Date: A Key Day Investors Track

Under the Prescription Drug User Fee Act (Prescription Drug User Fee Act, PDUFA), drug companies pay application fees in exchange for the FDA’s commitment to complete its review within a specified timeframe. This review deadline is the widely tracked PDUFA Date (PDUFA Date).

According to the FDA’s guidance, the review goal is 6 months for priority review applications and 10 months for standard review applications (source: FDA Priority Review). Because PDUFA dates are typically disclosed months in advance, the market has ample time to price in expectations—one reason these events can drive significant options activity.

Three Possible FDA Outcomes

The FDA’s decision generally falls into one of three outcomes:

• Approval: The drug can be formally marketed and sold. For small- and mid-cap biotech companies reliant on a single drug, an approval can sometimes drive the stock sharply higher in a short period.
• Complete Response Letter (Complete Response Letter, CRL): The FDA declines to approve the application in its current form and identifies data gaps or issues that must be addressed; the stock often drops meaningfully.
• Review extension: The FDA announces it needs additional time to complete the review, and the stock is typically affected as well.

Tip: Large pharmaceutical companies (for example, some with market capitalizations exceeding USD 100 billion) are generally far less sensitive in share price to an FDA decision on an individual drug than small single-asset companies, because their revenue sources are more diversified.

Advisory Committee (AdCom): A Pre-Decision Warning Signal

For some applications, the FDA convenes an Advisory Committee (Advisory Committee, AdCom) meeting—made up of external drug experts—weeks to months before the formal PDUFA date, to vote on the drug’s efficacy and safety.

According to an academic study covering FDA approvals from 2008 to 2015, the FDA’s final decision aligned with the advisory committee’s recommendation about 78% of the time (source: Milbank Quarterly study, PMC). As a result, the advisory committee vote itself also becomes a preceding options event that can influence the stock price.

Understanding Implied Volatility and IV Crush

The core challenge in trading FDA options events is often not predicting the direction of the decision, but understanding the dynamics of implied volatility (Implied Volatility, IV).

What Is Implied Volatility?

Implied volatility is the market’s expectation of the magnitude of a stock’s future price swings, embedded in options pricing. When uncertainty around a major event is high, options buyers are willing to pay higher premiums (i.e., option premium), pushing IV higher; once the outcome is announced, uncertainty dissipates and IV declines.

IV Crush: You Can Be Right on Direction and Still Lose Money

IV Crush (implied volatility crush) refers to the rapid drop in IV after a major event, which can cause option premiums to shrink dramatically. This is a major trap for long option holders: even if your directional call on the approval outcome is correct, the option premium loss driven by IV Crush can sometimes offset or even exceed the directional gain.

Ahead of an FDA binary event, biotech IV often rises substantially; after the announcement, IV may fall back quickly—and sometimes more violently than the IV Crush commonly seen after earnings for large-cap tech stocks.

Note: A hypothetical example to illustrate the mechanism: Stock A’s at-the-money call (ATM Call) is priced at USD 8 per contract before the PDUFA date. After approval, the stock rises 5%, but because IV collapses from 120% to 35%, the option’s market value may instead fall to USD 4–5. This example is purely hypothetical and is used to illustrate how IV Crush works.

Characteristics of Pre-Decision Options Strategies

Because the PDUFA date can be tracked in advance, some investors establish positions weeks before the decision announcement. Below are several common pre-positioning strategies and their characteristics, for educational reference only.

Long Straddle

A long straddle (Long Straddle) involves simultaneously buying a call (Call) and a put (Put) on the same stock with the same expiration date and the same strike price. The strategy does not require a clear directional view; the core thesis is that the stock will move significantly after the decision.

• Potential advantage: If the stock’s move exceeds the total premium paid, the position can theoretically be profitable.
• Key risk: Because IV is often already elevated ahead of an FDA event, straddles can be expensive. If the realized move is smaller than what is implied by the premium, or if IV Crush is severe, the buyer may incur losses.

Long Strangle

A long strangle (Long Strangle) is similar to a straddle, but the call and put are purchased at different strike prices: the call strike is typically above the current stock price, and the put strike is below it. Because both options are out-of-the-money (Out-of-the-Money, OTM), the cost is generally lower than a straddle—but it requires a larger stock move to break even.

Directional Options (Directional Calls/Puts)

If an investor has a clear directional view on the approval outcome, they may choose to buy calls (Call) or puts (Put) outright. Compared with holding the stock directly, the maximum loss is theoretically limited to the premium paid; however, the position is still exposed to IV Crush.

Tip: According to academic research cited by Columbia Law School’s CLS Blue Sky Blog, options trading activity ahead of FDA-related decisions is often more active than normal levels, reflecting active pricing of event risk (source: CLS Blue Sky Blog). Investors should be aware that option premiums at such times may already include a meaningful event premium.

Post-Decision Strategy Considerations

Once the decision is announced, the market regime can shift quickly. The strength of the IV Crush, together with the direction and magnitude of the stock’s realized move, jointly determines P&L outcomes across different options positions.

Seller Strategies (Short Premium): Considerations in a High-IV Environment

Elevated IV ahead of the decision allows option sellers (Short Option) to collect relatively rich premiums. For example, selling a bear call spread (Bear Call Spread) or a bull put spread (Bull Put Spread) can benefit from the post-event IV drop while keeping maximum loss capped.

However, the binary risk inherent in biotech FDA events cannot be ignored: if the outcome surprises the market, the stock’s one-day move can be extremely large and may easily break through the defined protection range of structured spread strategies. CRL (rejection letter)-driven declines can sometimes be more severe than the market expected.

After the Event: Liquidity and Exit Considerations

After the FDA outcome is announced, liquidity in the related options may deteriorate quickly, and bid-ask spreads (Bid-Ask Spread) may widen substantially—making short-term exits more difficult. Using limit orders (Limit Order) can better control execution prices and help avoid unfavorable fills in low-liquidity conditions. To learn more about the difference between limit orders and market orders in options execution, see the related article from Longbridge Academy.

Key Risks in Managing FDA Options Events

FDA options events involve multiple layers of risk. Below are several dimensions that merit particular attention.

Asymmetry of Binary Events

FDA events are “binary events” (Binary Event): outcomes are essentially one or the other, and their impact on a stock can be highly asymmetric. For example, a small biotech company might see its stock surge on approval, but a rejection could also cause a very large drop—and the magnitude in each direction may not be symmetrical. This asymmetry means investors cannot evaluate strategies using a simplistic “up or down” binary framework alone.

Event Premium Embedded in Options Prices

Ahead of the PDUFA date, option pricing often already embeds a substantial event premium (Event Premium). If the stock’s realized move after the event is smaller than the market expected, investors may fail to profit—even if they are directionally correct—because they paid too much premium. Some market participants believe establishing positions weeks before the event may involve a relatively lower IV level than entering very close to the decision date.

Position Sizing and Risk Concentration

Because an FDA event can cause violent, one-way stock moves, position sizing is especially important. Concentrating exposure in a single FDA options event can create disproportionate risk for an overall portfolio. Some market participants choose to diversify across multiple FDA events occurring at different times to reduce concentration risk.

Information Being Priced In Early

According to academic research cited by Columbia Law School’s CLS Blue Sky Blog, some studies find abnormal options trading activity ahead of FDA announcements, suggesting potential information asymmetry in the options market. For ordinary investors, this implies that ahead of the PDUFA date, the market price may already reflect a substantial amount of expectations—further compressing potential return opportunities.

Tip: You can track PDUFA dates via the FDA’s official website (FDA Novel Drug Approvals page) or via independent biotech data platforms. These platforms aggregate public information such as company announcements and SEC filings.

How to Track FDA Options Events

Systematically tracking the FDA approval calendar is the first step in participating in such events.

Primary Information Sources

• FDA official website: Provides records of approved drugs, but not a real-time PDUFA calendar.
• SEC filings: Drug companies often disclose PDUFA dates in SEC Form 8-K (material event disclosures) or in quarterly reports.
• Independent biotech data platforms: Aggregate company announcements and SEC filings to provide searchable, filterable PDUFA calendars, making it easier to track multiple potential events.

Combining Options Market Data for Analysis

After confirming the PDUFA date, it is also important to assess the current IV level relative to its historical percentile (IV Percentile). Options with IV already at historical highs typically imply higher costs for buyer strategies and may face a larger IV Crush; conversely, if IV remains in the mid-to-low range, it may indicate the market has not fully priced in the upcoming event.

Longbridge Securities provides U.S. stock options trading services. Users can learn more on Longbridge Securities’ investment products page, or track market moves via the Longbridge market data tools.

Frequently Asked Questions

What is the typical magnitude of a stock’s move around an FDA decision?

Historically, small-cap biotech stocks that receive approval may sometimes rise significantly in a short period, while stocks receiving a Complete Response Letter (CRL) often see a pronounced decline. Large pharmaceutical companies typically experience smaller moves. Past performance does not predict future results; the specific impact of each event depends on how important the drug is to the company and on market expectations.

What is IV Crush, and why is it unfavorable for options buyers?

IV Crush (implied volatility crush) refers to the rapid decline in implied volatility after a major event, which causes option premiums to shrink significantly. For options buyers, even if the stock moves in the expected direction, the premium loss caused by IV Crush can sometimes offset or even exceed directional gains, because buyers must bear the value erosion that comes with the dissipation of uncertainty-driven premiums.

What is the difference between a straddle and a strangle?

A straddle (Straddle) involves buying a call and a put at the same strike price; a strangle (Strangle) involves buying a call and a put at different strike prices (typically out-of-the-money). A strangle generally has a lower initial cost than a straddle, but requires a larger stock move to break even. Both are exposed to IV Crush risk.

How can I find the PDUFA date?

The PDUFA date is typically disclosed by the applicant company in its SEC filings (especially Form 8-K) or in investor relations announcements. The FDA itself does not provide a unified PDUFA calendar; independent biotech data platforms offer searchable calendar tools by aggregating public information.

Is event-driven options trading suitable for every investor?

Event-driven options trading involves complex risk factors, including binary outcome uncertainty, the impact of IV Crush, and liquidity risk; price swings can be extremely violent. Investors should fully understand how options work and their own risk tolerance, and carefully assess their experience and objectives before considering participation. All investments involve risk and may result in the loss of part or all of principal.

Summary

FDA drug approvals are among the most representative options events in the biotech market. Their binary outcomes, predictable timelines, and potentially violent market reactions create a distinctive trading environment for the options market.

Understanding the PDUFA date, the advisory committee mechanism, the dynamics of IV Crush, and the basic characteristics of strategies such as straddles and strangles forms the foundation for navigating this area. However, the high uncertainty of FDA events, the event premium embedded in option premiums, and the outsized volatility risk associated with binary outcomes are also core challenges investors must take seriously.

Which tool to use depends on an investor’s objectives, risk tolerance, market view, and level of experience. Regardless of the instrument chosen, investors must fully understand its mechanics, risk characteristics, and trading rules, and develop a robust risk management plan. You can learn more about investing via Longbridge Academy or download the Longbridge App to expand your investing knowledge.